Ebb & Flow

With the third quarter underway, those looking for a reading on the health of the IPO window in the U.S. may get some clear signals this week. Two companies - TolerRx and Phase Forward - are expected to price. And Idenix, a potential bellwether IPO, has firmed up its plans.

The picture is mixed in Europe, where watchers received conflicting signals last week. On one hand, bioMerieux (Euronext:BIM) got out and Epigenomics firmed up its plans. On the flip side, Microscience postponed its offering and now is looking to raise money privately...